Drugs & Therapy Perspectives

, Volume 5, Issue 11, pp 5–8 | Cite as

Filgrastim: an important advance in the treatment of severe chronic neutropenia

New Drugs and Therapeutics


Neutropenia Levodopa Acute Myeloid Leukaemia Filgrastim Entacapone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Frampton JE, Lee CR, Faulds D. Filgrastim: a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994 Nov; 48(5): 731–60PubMedCrossRefGoogle Scholar
  2. 2.
    Boxer LA, Hutchinson R, Emerson S. Recombinant human granulocyte-colony-stimulating factor in the treatment of patients with neutropenia. Clin Immunol Immunopathol 1992 Jan; 62(1): S39–S46PubMedCrossRefGoogle Scholar
  3. 3.
    Wilson JD, et al., editors. Harrison’s principles of internal medicine, 12th ed. New York: McGraw-Hill, 1991: 361Google Scholar
  4. 4.
    Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993 May 15; 81: 2496–502PubMedGoogle Scholar
  5. 5.
    Bonilla MA, Dale D, Zeidler C, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol 1994 Dec; 88: 723–30PubMedCrossRefGoogle Scholar
  6. 6.
    Fazio MT, Glaspy JA. The impact of granulocyte colony-stimulating factor on quality of life in patients with severe chronic neutropenia. Oncol Nurs Forum 1991; 28(8): 1411–4Google Scholar
  7. 7.
    Jones EA, Bolyard AA, Dale DC. Quality of life of patients with severe chronic neutropenia receiving long-term treatment with granulocyte colony-stimulating factor. JAMA 1993 Sep 1; 270: 1132–3PubMedCrossRefGoogle Scholar
  8. 8.
    Grant SM, Heel RC. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): a review of its pharmacological properties and prospective role in the management of myelosuppression. Drugs 1992; 43: 516–60PubMedCrossRefGoogle Scholar
  9. 9.
    Welte K, Zeidler C, Reiter A, et al. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 1990; 75: 1056–63PubMedGoogle Scholar
  10. 10.
    Freund MRF, Luft S, Schöber C, et al. Differential effect of GM-CSF and G-CSF in cyclic neutropenia. Lancet 1990; 336: 313PubMedCrossRefGoogle Scholar
  11. 11.
    Mori PG, Pasino M, Dufour C, et al. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and rhG-CSF in the treatment of a child with severe chronic neutropenia. Blood 1994 Nov 1; 84: 3244–5PubMedGoogle Scholar
  12. 12.
    Kaczmarski RS, Pozniak A, Lakhani A, et al. A pilot study of low-dose recombinant human granulocyte-macrophage colony stimulating factor in chronic neutropenia. Br J Haematol 1993 Jun; 84: 338–40PubMedCrossRefGoogle Scholar
  13. 13.
    Woermann UJ, Schenk R, Zimmermann A, et al. Increased bone metabolism in a patient undergoing long-term rhG-CSF treatment for idiopathic acquired neutropenia. Ann Hematol 1993 May; 66: 267–8PubMedCrossRefGoogle Scholar
  14. 14.
    Imashuku S, Hibi S, Kataoka-Morimoto Y, et al. Myelodysplasia and acute myeloid leukaemia in cases of aplastic anaemia and congenital neutropenia following G-CSF administration. Br J Haematol 1995 Jan; 89: 188–90PubMedCrossRefGoogle Scholar
  15. 15.
    Weinblatt ME, Scimeca P, James-Herry A, et al. Transformation of congenital neutropenia into monosomy 7 and acute nonlymphoblastic leukemia in a child treated with granulocyte colony-stimulating factor. J Pediatr 1995 Feb; 126: 263–5PubMedCrossRefGoogle Scholar
  16. 16.
    Jayabose S, Tugal O, Sandoval C, et al. Recombinant human granulocyte colony stimulating factor in cyclic neutropenia: use of a new 3-day-a-week regimen. Am J Pediatr Hematol Oncol 1994 Nov; 16: 338–40PubMedGoogle Scholar
  17. 17.
    Kaczmarski RS, Mufti GJ. Low-dose filgrastim therapy for chronic neutropenia [letter]. N Engl J Med 1993 Oct 21; 329: 1280–1PubMedCrossRefGoogle Scholar
  18. 18.
    British National Formulary No. 29. London: The Pharmaceutical Press, 1995; 357Google Scholar

Copyright information

© Adis International Ltd 1995

Personalised recommendations